302 related articles for article (PubMed ID: 33373797)
1. Tumefactive multiple sclerosis (TMS): A case series of this challenging variant of MS.
Villarreal JV; Abraham MJ; Acevedo JAG; Rai PK; Thottempudi N; Fang X; Gogia B
Mult Scler Relat Disord; 2021 Feb; 48():102699. PubMed ID: 33373797
[TBL] [Abstract][Full Text] [Related]
2. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
3. Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.
Croteau D; Tobenkin A; Brinker A; Kortepeter CM
Mult Scler; 2021 May; 27(6):903-912. PubMed ID: 32662718
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic inertia in relapsing-remitting multiple sclerosis.
Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
[TBL] [Abstract][Full Text] [Related]
5. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.
Maniscalco GT; Saccà F; Lanzillo R; Annovazzi P; Baroncini D; Binello E; Repice A; Perini P; Clerico M; Mataluni G; Bonavita S; La Gioia S; Gutierrez LP; Laroni A; Frau J; Cocco E; Torri Clerici V; Zarbo IR; Sartori A; Signoriello E; Rasia S; Cordioli C; Stromillo ML; Cerqua R; Pontecorvo S; Di Sapio A; Grasso R; Barone S; Lavorgna L; Barrilà C; Landi D; Russo CV; Frigeni B; Ippolito D; Turano G; Carmisciano L; Sormani MP; Signori A
Mult Scler Relat Disord; 2020 Jul; 42():102059. PubMed ID: 32208344
[TBL] [Abstract][Full Text] [Related]
6. Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota.
Pilotto S; Zoledziewska M; Fenu G; Cocco E; Lorefice L
Mult Scler Relat Disord; 2023 May; 73():104671. PubMed ID: 37001407
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
8. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
10. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
11. The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients.
Dabbaghi R; Safaralizadeh R; Rahmani S; Barpour N; Hosseinpourfeizi M; Rajabi A; Baradaran B
BMC Res Notes; 2023 Oct; 16(1):273. PubMed ID: 37845751
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of dimethyl fumarate as first line therapy in MS patients - one center real life observation study.
Sałacińska D; Pogoda A; Żółkiewicz J; Stępień A
Pol Merkur Lekarski; 2019 Dec; 47(282):221-225. PubMed ID: 31945023
[TBL] [Abstract][Full Text] [Related]
13. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.
Lucchinetti CF; Gavrilova RH; Metz I; Parisi JE; Scheithauer BW; Weigand S; Thomsen K; Mandrekar J; Altintas A; Erickson BJ; König F; Giannini C; Lassmann H; Linbo L; Pittock SJ; Brück W
Brain; 2008 Jul; 131(Pt 7):1759-75. PubMed ID: 18535080
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
16. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
17. Concurrent glioma and multiple sclerosis: A systematic review of case reports.
Nafari A; Ghaffary EM; Shaygannejad V; Mirmosayyeb O
Mult Scler Relat Disord; 2024 Apr; 84():105455. PubMed ID: 38330723
[TBL] [Abstract][Full Text] [Related]
18. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
Jeung L; Smits LMG; Hoogervorst ELJ; van Oosten BW; Frequin STFM
Mult Scler Relat Disord; 2020 May; 40():101978. PubMed ID: 32062445
[TBL] [Abstract][Full Text] [Related]
19. A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.
Das J; Gill A; Lo C; Chan-Lam N; Price S; Wharton SB; Jessop H; Sharrack B; Snowden JA
Front Immunol; 2020; 11():668. PubMed ID: 32431694
[TBL] [Abstract][Full Text] [Related]
20. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
